Examine Detailed Profiles of Key Compounds in Development for Use in Bipolar Disorder, With Forecasts of Drug Revenues To 2015.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42440) has announced the addition of the new report from Datamonitor "Pipeline Insight: Bipolar Disorder - New Treatments for Bipolar Depression Set to Drive Near-term Growth" to their offering.

Stimulated by sales of atypical antipsychotics for bipolar depression, and despite the launch of generic risperidone, the global bipolar disorder market will grow until 2011, when revenues will peak at $6.6 billion. The market will begin to decline thereafter owing to the launch of generic versions of the leading atypical antipsychotics, quetiapine, olanzapine, and ziprasidone from 2011 onwards.

Highlights of this title include:

AstraZeneca will be the first company to bring an atypical antipsychotic to the bipolar depression market as a monotherapy, following demonstration of efficacy with quetiapine. Pfizer will maintain a strong schizophrenia franchise by releasing asenapine to buffer the loss in revenue due to genericization of ziprasidone.

Solvay/Wyeth/Lundbecks bifeprunox will be the leading market entrant in terms of bipolar disorder specific sales revenue. These companies appear to be seeking initial license for bifeprunox in the bipolar depression indication, a tactic that will both increase the commercial viability of the drug and save time/money.

Despite the commercial success of Lamictal (lamotrigine) and Depakote (valproate), the late-stage bipolar disorder pipeline only includes one anticonvulsant class molecule, Novartis licarbazepine.

Scope of this title:

This report provides an analysis of patient potential, unmet needs and clinical trial design in bipolar disorder. It also gives an overview of drugs in pre-registration, Phase III, II and I; with analysis of key companies involved in the market. The report gives detailed profiles of key compounds in development for use in bipolar disorder, with forecasts of drug revenues to 2015. It also discusses expansion strategies and insight from key industry opinion leaders.

Reasons to order your copy:

This report helps readers to understand unmet needs in the bipolar disorder market based on key opinion leader comments. It benchmarks key late-stage bipolar disorder compounds against current market leaders. It provides an assessment of the global (US, Japan, five major EU) sales forecasts of late-stage pipeline drugs; and examine their clinical and commercial potential.

Key Topics Covered Include:

--Patient potential

--Definition of bipolar disorder

--Characteristics of bipolar disorder phases

--Segmentation of bipolar disorder subtypes

--Bipolar I disorder

--Bipolar II disorder

--Bipolar III disorder (cyclothymia)

--Current treatment paradigms for bipolar disorder

--Treatment of manic episodes associated with bipolar disorder

--Maintenance and prophylactic therapy

--Treatment of bipolar depression

--Off-label use of antidepressants for bipolar disorder treatment

--Classification of pipeline drugs seeking indication in bipolar disorder

--Positive and Negative Syndrome Scale

--Generic incursion expected when key CNS products come off-patent

--Follow-on antipsychotic may not be sufficiently differentiated

--Drug overview: indication expansion into bipolar depression imminent

For more information visit http://www.researchandmarkets.com/reports/c42440

Source: Datamonitor